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Abstract 
Myasthenia gravis (MG) is an autoimmune 
disorder of the neuromuscular junction. 
Preeclampsia/HELLP Syndrome is a potentially 
life-threatening pregnancy complication. The 
combination of HELLP Syndrome and MG is 
challenging because the preferred treatment 
regimens for both conditions generally contradict 
each other. Our aim is to describe the 
management options when these two diseases 
occur simultaneously. We present a case in 
which a woman with an established diagnosis of 
MG developed HELLP Syndrome at 31 weeks 
gestation. Magnesium sulfate prophylaxis was 
not utilized because of the patient’s MG 
diagnosis. A cesarean delivery was performed. 
Reported cases with combined diagnoses of MG 
and preeclampsia/HELLP Syndrome are 
reviewed and adjustments to treatment plans 
are discussed. Management of such patients 
should be done with a multidisciplinary approach 
in advanced medical centers with careful 
consideration of the medications used. 
1Kanuni Sultan Suleyman Training and 
Research Hospital, Department of Obstetrics 
and Gynecology, Istanbul, Turkey 
 
Introduction 
Myasthenia gravis (MG) is an 
autoimmune disorder of the 
neuromuscular junction. IgG 
autoantibodies directed against the 
postsynaptic nicotinic acetylcholine 
receptor (AChR) result in skeletal 
muscle weakness and easy fatigue, with 
episodic exacerbation and remission. 
Muscle weakness can be asymmetric, 
generalized, or involve only a single 
muscle group. The extraocular muscles 
are most commonly affected, with 
resultant diplopia and ptosis. Problems 
such as laryngeal and pharyngeal 
muscle weakness, dysarthria, chewing 
and swallowing difficulties, and inability 
to clear secretions are the result of 
bulbar involvement. In severe cases, 
proximal muscle weakness (neck and 
shoulder) and involvement of respiratory 
muscles occur. Characteristically, 
muscle weakness decreases with rest 
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and increases with effort. Infection, 
stress, surgery, and pregnancy lead to 
exacerbations in one third of the 
population.1 Myasthenia gravis is a rare 
condition in pregnancy.2 The incidence 
of myasthenia gravis among women of 
reproductive age is 1/10,000-1/50,000.3 
As in many other autoimmune diseases, 
MG is more common in women than in 
men.4 It occurs most frequently in 
women in their third decade. As far as 
we know from the information in 
literature, pregnancy is known to have a 
variable effect on myasthenia gravis (1/3 
stability, 1/3 healing, 1/3 exacerbation). 
MG exacerbations with pregnancy are 
most common in the first trimester and 
the puerperium. Relative 
immunosuppression in the second and 
third trimesters results in fewer disease 
exacerbations during these periods.5 
Pyridostigmine bromide and 
prednisolone may be used in the 
treatment of pregnant women with MG. 
Due to fetal teratogenic effects, 
immuno-suppressive therapies are not 
recommended.6 
Preeclampsia is a pregnancy-specific 
syndrome that increases the risks of 
maternal and fetal morbidity and 
mortality. HELLP (hemolysis, elevated 
liver enzymes, and low platelet count) 
Syndrome is a life-threatening condition 
that sometimes occurs during 
pregnancy. Although some form of 
hypertensive disease of pregnancy 
(preeclampsia, HELLP Syndrome, 
eclampsia) occurs in approximately 6-
8% of all pregnancies, the simultaneous 
occurrence of preeclampsia or HELLP 
Syndrome and MG in pregnancy is very 
rare.7  
In this article, we describe a pregnant 
woman with a previous diagnosis of MG 
who subsequently developed HELLP 
Syndrome. We also discuss 
management options with the co-
occurrence of these two diseases in 
pregnancy. 
Case report  
A 34-year-old nulliparous woman at 31 
weeks gestation was admitted to our 
emergency department due to epigastric 
pain and severe headache. She had 
been diagnosed with myasthenia gravis 
four years previous and had no other 
comorbid diseases. She stated that she 
received 60 mg pyridostigmine four 
times a day and that her MG had 
remained under control during 
pregnancy. At the beginning of 
pregnancy, she had received 40 mg 
pyridostigmine three times a day. 
However, dosage and frequency were 
increased when she was diagnosed with 
myasthenic crisis demonstrated by the 
sudden development of breathing 
difficulty and weakness in the hands and 
feet in the last two weeks of pregnancy. 
She stated that she had no other 
complications during her pregnancy. 
On fetal evaluation, a non-stress test 
(NST) was normal. Ultrasonography 
revealed a vertex fetus with a normal 
amniotic fluid index and growth. The 
patient reported good fetal movement. 
Pelvic examination showed no cervical 
dilatation. On physical examination, her 
blood pressure was 210/140 mmHg. Her 
hemoglobin level was 14 g/dl and 
platelet count was 33,000/ml. Her serum 
aspartate aminotransferase (696 U/l), 
alanine aminotransferase (370 U/l), and 
lactate dehydrogenase (501 U/L) levels 
were high. There was 3+ proteinuria. 
Total bilirubin, prothrombin time, and 
partial thromboplastin time were within 
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normal limits. Neurological examination 
revealed 4/5 muscle strength in both 
proximal and distal muscles.  
Using findings from a second set of 
laboratory tests performed two hours 
later, it was determined that the patient 
did not have bleeding. However, the 
patient's hemoglobin level was 11 g/dl, 
and her platelet level was 31,000/ml. In 
addition, AST was 750 U/l, ALT was 410 
U/l, fibrinogen was 510 mg/dl, indirect 
bilirubin was 1.3 mg/dl, LDH level was 
756 U/L, haptoglobin level was 15 
mg/dl, urea was 45 mg/dl, 
albumin/creatinine was 3.8 mg/dl, and 
coagulation parameters were observed 
to be normal. A peripheral spread of the 
patient was made, and schistocytes 
were observed. D-dimer levels were 
found to be normal.  
The patient was hospitalized with 
diagnoses of MG and preeclampsia 
complicated by HELLP syndrome. The 
severity of the HELLP syndrome was 
defined according to the Mississippi 
Triple Class System. Based on this 
system, our patient was classified as 
Class 1 (high) due to high liver 
enzymes, hemolysis and a thrombocyte 
count lower than 50.000/ml.  
Based on clinical findings of HELLP 
Syndrome and the second set of 
laboratory findings, it was decided that 
urgent cesarean delivery was 
necessary, primarily because of high 
AST and ALT levels. In addition, 
hemoglobin values decreased without 
any sign of bleeding, there was a 
decrease in the haptoglobin value, and 
there was an increase in the indirect 
bilirubin. The patient was taking 
medication for myasthenia gravis. Six 
units of random donor platelets were 
given to the patient pre-operatively and 
short-term phenytoin therapy was 
started.  
Magnesium sulfate treatment typically 
used to treat HELLP Syndrome was not 
initiated because it increases the 
chance of crisis in myasthenic patients. 
However, short-term phenytoin 
treatment was initiated because it is 
suggested for the seizure prophylaxis in 
myasthenic patients who have HELLP 
Syndrome or who are preeclamptic. Due 
to her worsening clinical condition, 
emergency cesarean section was 
performed under general anesthesia 
since her platelet count was very low 
(33,000/ml). A healthy baby boy of 1680 
g was born with 1-minute and 5-minute 
Apgar scores of 8 and 9. The baby was 
hospitalized in the intensive care unit 
due to prematurity. Newborn 
examination revealed no neonatal 
myasthenia gravis.  
Postoperatively, the mother was 
transferred to the intensive care unit. 
AST and ALT values gradually returned 
to normal. In addition, platelet value 
approached normal. The critical 
laboratory values of the patient during 
hospitalization are listed in Table-1. The 
patient's respiratory parameters were 
carefully monitored. 70 mg 
dexamethasone was intravenously 
administered postoperatively. Because 
the patient had systolic blood pressure 
values of 220 to 200 mmHg and 
diastolic blood pressure values of 140 to 
120 mmHg, perlinganit infusion and 250 
mg oral methyldopa (2 tablets 4 times 
per day) were started.  
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Table 1: Biochemical and hematological data 
 Admission Second day Third day Seventh day Eleventh day 
Hb (g/dl) 14 12 8.8 9 8.8 
Ht 43 37 28 29 29 
Platelet (cells/ml) 33 55 62 79 90 
AST (U/l) 696 397 87 35 22 
ALT (U/l) 370 306 72 40 29 
LDH 501 486 320 280 240 
 
In the postoperative period, 60 mg 
pyridostigmine was initiated four times a 
day for the patient. However, when 
sudden breathing difficulty started 24 
hours after the caesarean, it was 
considered a myasthenic crisis and the 
dosage of pyridostigmine was increased 
to 60 mg six times a day. The patient 
was followed up in the intensive care 
unit for nine days postoperatively for the 
possible myasthenic crisis. During the 
follow-up period, she did not have an 
MG crisis again and continued to 
receive methyldopa, pyridostigmine, and 
dexamethasone.  
On postoperative day two, no 
deteriorations were observed in the 
clinical findings of the patient. The 
laboratory findings were as follows; 
hemoglobin 12 gr/dl, hematocrit 37, 
platelet 55,000/ml, AST 397 U/l, ALT 
306 U/l and LDH 486 U/l. However, on 
the fifth postoperative day, doxazosin 
mesylate and valsartan were added to 
the treatment since blood pressure 
values had not fallen to normal levels.  
On the seventh day in the ICU, the 
tension values of the patient decreased, 
and laboratory values were as follows: 
hemoglobin 9 gr/dl, hematocrit 29, 
platelets 79,000/ml, AST 35 U/l, ALT 40 
U/l and LDH 280 U/l. The patient was 
discharged from the ICU on the ninth 
day after her admission to the hospital. 
The patient was discharged from the 
hospital on the eleventh day after 
admission because she had hemoglobin 
8.8 gr/dl, hematocrit 29, platelet 
90,000/ml, AST 22 U/l, ALT 29 U/l and 
LDH 240 U/l and tension values were 
completely normal. Methyldopa 250 mg 
(2 times per day) and pyridostigmine 40 
mg (2 times per day) were prescribed at 
hospital discharge. At the sixth month 
postpartum, the patient’s blood pressure 
values were within normal limits and her 
myasthenia gravis was under control. 
Discussion  
Coexistence of MG and 
HELLP/preeclampsia is very rarely 
seen. There are conflicts in treatment 
methods in cases with a combination of 
the two diseases. In other words, the 
treatment of one disease may worsen 
the clinical course of the other disease. 
There are many factors that can trigger 
a crisis in myasthenic patients. For 
example, both medical conditions and 
medications may aggravate MG. These 
can include pregnancy, thyroid 
dysfunction, and postpartum use of 
aminoglycoside, tetracycline, 
magnesium, β-blockers, and calcium 
channel blockers. Table 2 represents a 
detailed list of these factors and 
medications. When there is a 
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comorbidity in patients with MG, 
treatment must be handled with care to 
assure successful patient management. 
Table 2: Factors that can aggravate MG8 
1. Pathophysiological 
 Stress response: infection, surgery, trauma, pain or emotional stress 
Pregnancy and post-partum 
Temperature: hypothermia or hyperthermia 
Thyroid dysfunction: hypothyroidism or hyperthyroidism 
2. Pharmacological 
 Inadequate dosing of anticholinesterase medication 
Antibiotics: aminoglycosides, tetracyclines, others (erythromycin, clindamycin, lincomycin, 
ciprofloxacin, ampicillin) 
Cardiovascular drugs: β-blockers, calcium-channel blockers, quinine, quinidine, procainamide, 
lidocaine 
Magnesium 
Anesthetic drugs: volatile agents, neuromuscular blocking agents, local anesthetics 
Others: phenytoin (long-term treatment), gabapentin, lithium, penicillamine, corticosteroids, opioids, 
iodinated contrast agents, frusemide, thyroxine 
 
When MG and preeclampsia/HELLP 
Syndrome are seen simultaneously in 
patients, the most important step in the 
treatment of preeclampsia is to control 
hypertension. In normal cases, the first-
line choice of drugs is labetalol, with 
methyldopa and nifedipine as second-
line choices. However, labetalol is a 
beta blocker, and nifedipine is a calcium 
channel blocker. Both drug groups may 
exacerbate an MG crisis. Therefore, 
methylphenidate or hydralazine become 
the first choices for patients with MG.9,10 
Similarly, magnesium sulfate therapy is 
the first-line treatment to prevent crisis 
in preeclamptic patients.11 However, 
while magnesium sulfate treatment 
serves well for the prophylaxis of 
eclampsia crises, it also causes 
blockage in the neuromuscular junction 
in patients with MG and may exacerbate 
MG symptoms.12 If patients with MG are 
treated with magnesium sulfate therapy, 
it causes dose-dependent side effects 
such as fatigue, facial twitch, 
arrhythmia, and muscle weakness. In 
brief, magnesium sulfate treatment 
cannot be safely used to avoid 
eclampsia crises in patients in whom 
MG and HELLP/preeclampsia coexist. 
As mentioned previously, release of 
excessive amounts of magnesium 
prevents presynaptic acetylcholine 
release in the neuromuscular junction 
and avoids postsynaptic stimulation. 
Instead, short-term phenytoin therapy is 
recommended for eclampsia prophylaxis 
in patients with a combination of MG 
and hypertensive disorders of 
pregnancy. However, long-term use of 
phenytoin has the potential of 
exacerbating myasthenia gravis (Table 
2).13  
Provided that there is no obvious 
respiratory disorder or bulbar 
dysfunction in the patient, local 
anesthesia is preferred for cesarean 
section in myasthenic patients. Ester 
local anesthetics are recommended 
because they might have a longer half-
life in patients receiving 
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anticholinesterase treatment, depending 
on the inhibition of their plasma 
cholinesterase.14 In cases where both 
diseases coexist, some adaptions in 
treatment management may be needed 
as listed in Table 3. 
Table 3: Management goals in preeclampsia, usual therapy and modifications in 
myasthenia gravis8 
Management goal Usual treatment Modifications in myasthenia gravis 
Maintenance of appropriate blood 
pressure 
Non-severe hypertension (systolic 
pressure140–159 mm Hg and 
diastolic 90–109 mm Hg) 
 
 
 
Severe hypertension (systolic 
pressure >160 mm Hg and/or 
diastolic >110 mm Hg) 
 
 
Most guidelines recommend 
treatment9,10  
Options: oral labetalol, methyldopa, 
nifedipine, hydralazine 
 
 
Should be treated15  
Options: labetalol (oral/intravenous), 
nifedipine (oral), hydralazine 
(intravenous) 
 
 
β-Adrenoceptor blockers and calcium-
channel blockers have the potential to 
exacerbate weakness 
Consider methyldopa or hydralazine 
(oral) as first line therapy 
 
 
Consider hydralazine (intravenous) as 
first line therapy 
Use of labetalol (oral/intravenous) 
described16  
 
Seizure prevention and treatment 
Seizure prophylaxis 
 
 
 
Eclampsia treatment 
 
MgSO4 first line11  
 
 
 
MgSO4 first line11 
 
 
 
MgSO4 contraindicated12,17,18 
Consider phenytoin13  
Careful blood pressure control 
 
Morbidity/mortality benefit of MgSO4 
may outweigh risk of 
myasthenic crisis (especially if 
prolonged or recurrent seizures) 
Alternatives (diazepam, phenytoin) are 
inferior to MgSO4 
 
Prevention of pulmonary edema 
Fluid balance 
 
Cautious management of fluid 
balance (restrictive fluid therapy if 
normal renal function present 
 
Cautious management of fluid balance 
Safe general anesthesia 
General anesthesia 
 
 
Blood pressure control 
Cardiovascular response to 
laryngoscopy (eg, alfentanil, 
remifentanil) 
 
Consider intubation without muscle 
relaxant using alfentanil (up to 50 
mg/kg) or remifentanil 
If muscle relaxant required consider 
reduced-dose rocuronium with 
sugammadex reversal 
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In this article, we presented treatment 
management in a patient who had a 
previous diagnosis of MG and 
developed HELLP syndrome. 
Magnesium sulphate therapy could not 
be performed for eclampsia prophylaxis 
because it was accompanied by MG. 
The patient was started on short-term 
phenytoin therapy. Cesarean section 
was performed due to worsening clinical 
condition. We wanted to perform spinal 
anesthesia during surgery; however, 
general anesthesia had to be performed 
due to low platelet count. The patient 
was followed in the intensive care unit 
after surgery. She was discharged from 
the hospital on postoperative day 11.  
This patient exemplifies the risks posed 
for mother and child when a pregnant 
patient has the rare combination of 
concurrent myasthenia gravis and 
preeclampsia/HELLP Syndrome. There 
are conflicts in the management of 
these diseases. Medication options 
must be considered for general 
anesthesia, reduction of hypertension, 
seizure prophylaxis and other forms of 
treatment. Local anesthesia is a safer 
option in many cases.  
Previously published case reports have 
primarily documented patients with a 
combination of preeclampsia and MG. 
Only Spiezio et al.7 reported a case with 
a combination of MG and HELLP. 
Studies that have been published in 
PUBMED to date and have reported 
cases with a combination of MG and 
preeclampsia are presented in Table 4.  
Conclusion  
Pregnant women with MG who then 
develop hypertensive pregnancy 
complications should be managed in 
tertiary medical centers capable of 
providing respiratory support and high-
risk obstetric and neonatal care. 
Patients should be managed by a 
multidisciplinary team of obstetricians 
and gynecologists, neurologists, 
anesthesiologists, and neonatologists. 
Medications for such patients need to be 
considered carefully to avoid 
problematic interactions and 
unintentional exacerbation of either of 
the patient's medical conditions. 
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Table 4: Current myasthenic-preeclampsia/HELLP cases in the literature, 
MEDLINE search 
First Author Year Age G/P Birth 
Week 
Mode Medication Presentation 
Cohen BA12  1976 37 G3P1 Term C/S *Hypertensive treatment: 
Furosemide,  methyldopa 
*Anticonvulsant 
treatment: Magnesium 
sulphate 
The patient had a myasthenic 
crisis due to magnesium 
sulphate treatment. 
Duff GB19 1  1979 26 G2P1 37 C/S *Hypertensive treatment: 
methyldopa, diazoxide, 
reserpine, furosemide 
*Anticonvulsant 
treatment: Diazepam 
The patient was 
transferred to the ICU (about 
16 hours) 
Duff GB19 2  1979 36 G2P1 36 SVD *Hypertensive treatment: 
Ephedrine 
Prednisone started in the 
postpartum period. 
Brogan M20  1983 37 G1P0 32 C/S No information No information 
Bashuk RG21  1990 19 G1P0 Term SVD *Anticonvulsant 
treatment: Magnesium 
sulphate 
The patient became 
quadriplegic due to 
magnesium sulphate 
treatment. Magnesium 
sulphate treatment stopped. 
Benshushan 
A17  
1994 31 G1P0 31 SVD *Hypertensive treatment: 
Methyldopa, hydralazine 
Postpartum haemorrhage 
after delivery 
The patient was transferred to 
the ICU 
Di Spiezio 
Sardo A7  
2003 27 G2P0 37 C/S *Hypertensive treatment: 
Methyldopa 
The patient was diagnosed 
with severe preeclampsia 
complicated by HELLP 
Hamaoui A16  2009 31 G7P3 27 C/S *Hypertensive treatment: 
Hydralazine, metoprolol, 
losartan, amlodipine, 
labetalol. 
HELLP syndrome occurred 
postpartum third day 
Ozcan J8  2015 34 G1P0 36 C/S *Hypertensive treatment: 
Enalapril 
Pyridostigmine and IV 
immunoglobulin doses were 
increased in the postpartum 
period after the operation due 
to bradycardia 
Sikka  P22  2015 25 G1P0 36 C/S No information No information 
Lake AJ23  2017 28 G3P2 34 C/S *Hypertensive treatment: 
Hydralazine, labetalol 
*Anticonvulsant 
treatment: Levetiracetam 
In the postpartum period, 
levetiracetam was continued 
(only 2 days) and 
hypertension was treated with 
methyldopa and hydralazine. 
Clonidine was added on 
postpartum day 2 
G: Gravida, P: Parity, SVD: Spontaneous Vaginal Delivery, C/S: Caesarean Section, ICU: Intensive Care 
Unit 
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